387 related articles for article (PubMed ID: 31839172)
21. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
Watanuki R; Hayashida T; Kawai Y; Kikuchi M; Nakashoji A; Yokoe T; Toyota T; Seki T; Takahashi M; Kitagawa Y
Int J Clin Oncol; 2019 Jul; 24(7):807-814. PubMed ID: 30810890
[TBL] [Abstract][Full Text] [Related]
22. Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge.
Jackisch C; Cortazar P; Geyer CE; Gianni L; Gligorov J; Machackova Z; Perez EA; Schneeweiss A; Tolaney SM; Untch M; Wardley A; Piccart M
Cancer Treat Rev; 2021 Sep; 99():102229. PubMed ID: 34139476
[TBL] [Abstract][Full Text] [Related]
23. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Schramm A; Schochter F; Friedl TWP; de Gregorio N; Andergassen U; Alunni-Fabbroni M; Trapp E; Jaeger B; Heinrich G; Camara O; Decker T; Ober A; Mahner S; Fehm TN; Pantel K; Fasching PA; Schneeweiss A; Janni W; Rack BK;
Clin Breast Cancer; 2017 Jul; 17(4):279-285. PubMed ID: 28190761
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
[TBL] [Abstract][Full Text] [Related]
26. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
Estévez LG; Gradishar WJ
Clin Cancer Res; 2004 May; 10(10):3249-61. PubMed ID: 15161677
[TBL] [Abstract][Full Text] [Related]
27. Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience.
Matthews CM; Nymberg K; Berger M; Vargo CA; Dempsey J; Li J; Ramaswamy B; Reinbolt R; Sardesai S; Wesolowski R; Williams N; Lustberg M
J Oncol Pharm Pract; 2020 Apr; 26(3):572-579. PubMed ID: 31256745
[TBL] [Abstract][Full Text] [Related]
28. Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.
Clavarezza M; Puntoni M; Gennari A; Paleari L; Provinciali N; D'Amico M; DeCensi A
Clin Cancer Res; 2016 Sep; 22(18):4594-603. PubMed ID: 27140927
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
31. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
[TBL] [Abstract][Full Text] [Related]
32. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
[TBL] [Abstract][Full Text] [Related]
33. WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.
Hofmann D; Nitz U; Gluz O; Kates RE; Schinkoethe T; Staib P; Harbeck N
Trials; 2013 Aug; 14():261. PubMed ID: 23958221
[TBL] [Abstract][Full Text] [Related]
34. Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
Zardavas D; Fouad TM; Piccart M
Breast; 2015 Nov; 24 Suppl 2():S143-8. PubMed ID: 26255196
[TBL] [Abstract][Full Text] [Related]
35. Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials.
Carbognin L; Sperduti I; Nortilli R; Brunelli M; Vicentini C; Pellini F; Pollini GP; Giannarelli D; Tortora G; Bria E
Cancer Treat Rev; 2015 Mar; 41(3):262-70. PubMed ID: 25683304
[TBL] [Abstract][Full Text] [Related]
36. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
[TBL] [Abstract][Full Text] [Related]
37. Advances in targeting HER2-positive breast cancer.
Harbeck N
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):55-59. PubMed ID: 29194077
[TBL] [Abstract][Full Text] [Related]
38. Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Harbeck N
Breast; 2015 Nov; 24 Suppl 2():S44-8. PubMed ID: 26321480
[TBL] [Abstract][Full Text] [Related]
39. [Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].
Sun B; Song ST; Jiang ZF; Wang T; Zhang SH; Meng XY; Li XB; Yu CZ; Wu SK
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):38-42. PubMed ID: 23648298
[TBL] [Abstract][Full Text] [Related]
40. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
